ALTACE 1.25 MG
RAMIPRIL : 1.25 MG · DIN 02221829 · BAUSCH HEALTH, CANADA INC.
Health Canada status: MARKETED
What is ALTACE?
ALTACE 1.25 MG contains RAMIPRIL : 1.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02221829, held by BAUSCH HEALTH, CANADA INC., supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Jan-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ALTACE used for?
Essential hypertension; treatment following acute myocardial infarction in stable patients with LV dysfunction; reduction of risk of MI, stroke, or CV death in high-risk patients >55 years.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02221829 |
|---|---|
| Brand name | ALTACE |
| Generic / active ingredient | RAMIPRIL : 1.25 MG |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 1.25 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA05 RAMIPRIL |
| AHFS class | 24:32.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Jan-2021 |
| Original market date | 1997-05-28 00:00:00 |
How is it administered?
Hypertension: 2.5-20 mg/day. Post-MI: 2.5-5 mg bid. CV risk reduction: 2.5-10 mg/day. Correct volume depletion before start. Monitor renal function.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (refer to section 11 of full monograph).
How is it supplied?
Capsules (1.25, 2.5, 5, 10, 15 mg) and Tablets (1.25, 2.5, 5, 10 mg). Specific packaging counts not provided in text.
Contraindications
Hypersensitivity to ACE inhibitors; history of angioedema; pregnancy/nursing; bilateral renal artery stenosis; hypotensive/unstable states; concomitant use with sacubitril/valsartan or aliskiren.
Warnings and precautions
ACE inhibitors can cause fetal injury/death. Risk of angioedema (head/neck/intestinal), hypotension, neutropenia, and hepatic failure. Monitor renal function and white blood cell counts.
Is RAMIPRIL in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANIS HEALTH INC, last seen 19 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09AA05 RAMIPRIL. 55 of 171 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-RAMIPRIL | 10 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02477599 |
| AG-RAMIPRIL | 2.5 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02477572 |
| AG-RAMIPRIL | 5 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02477580 |
| ALTACE | 10 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02221853 |
| ALTACE | 2.5 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02221837 |
| ALTACE | 5 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02221845 |
| APO-RAMIPRIL | 1.25 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02251515 |
| APO-RAMIPRIL | 10 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02251582 |
| APO-RAMIPRIL | 15 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02325381 |
| APO-RAMIPRIL | 2.5 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02251531 |
Who else supplies RAMIPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RAMIPRIL appears in 752 registered pack listings across 15 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.